{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005223","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-08-05T11:02:39+00:00","discovered_at":"2026-08-05T11:05:00.318095+00:00","generated_at":"2026-08-05T11:06:25.937313+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst Q2 revenue $218.3M, GAAP operating profit $98.5M; raises total revenue guidance","bullets":["ORLADEYO net revenue $158.2M (+1% YoY); oral pellets shipping to pediatric patients began Aug 3.","GAAP operating profit $98.5M; non-GAAP operating profit $113.2M; cash $354M.","Raised FY2026 total revenue guidance to $690-715M; ORLADEYO guidance unchanged $625-645M.","Completed enrollment in navenibart pivotal study (ALPHA-ORBIT); top-line data expected Q3 2027.","Licensed navenibart European rights to Neopharmed Gentili for $70M upfront plus milestones/royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005223","json":"https://secwatch.observer/filing/0001171843-26-005223.json","markdown":"https://secwatch.observer/filing/0001171843-26-005223.md","text":"https://secwatch.observer/filing/0001171843-26-005223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/0001171843-26-005223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/f8k_080526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:06:25.937313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}